Blood Tests to Track Neuroblastoma During Treatment
Part of Cancer clinical trials.
This study collects blood samples from neuroblastoma patients to test for tiny pieces of tumor DNA that can show how well treatment is working. By tracking these markers over time, doctors hope to better predict how patients will respond and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with neuroblastoma (a childhood cancer of nerve cells)
- You are newly diagnosed, have relapsed (cancer came back), or have refractory or progressive disease
- You are willing to provide blood samples at the start and during follow-up appointments
- Your medical records contain information about your treatment response and outcomes
- You or your parent/guardian can provide written consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.
This study looks at the tumor’s molecular (genetic) features in people with neuroblastic tumors to see how those features relate to clinical outcomes. If you are treated with naxitamab as part of standard care, you may be eligible for the tumor/biomarker (test results) portion of the research.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.